Status:
COMPLETED
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Lead Sponsor:
Leti Pharma GmbH
Conditions:
Allergic Rhinoconjunctivitis
Allergic Asthma
Eligibility:
All Genders
12+ years
Brief Summary
The CSMS was defined by the European Academy of Allergy and Immunology Taskforce as a standardised tool to assess clinical effects of allergen-specific immunotherapy (AIT). The aim of this study is to...
Detailed Description
Approximately 20% of the general public suffer from seasonal or perennial allergic rhinoconjunctivitis. The only available curative therapy is AIT. The effectiveness of AIT was demonstrated in numerou...
Eligibility Criteria
Inclusion
- \- Indication of an allergen-specific immunotherapy with Depigoid
Exclusion
- \- exclusion criteria according to the SmPC
Key Trial Info
Start Date :
September 9 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 3 2020
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT03850626
Start Date
September 9 2018
End Date
September 3 2020
Last Update
March 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. med Andrea Kienle-Gogolok
Bad Schönborn, Germany, 76869